rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KRRO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Korro Bio: 10% owner Lynx1 Capital Management LP buys $884,751 stock
      Oct 26Investing.comKRRO
      Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?
      Oct 23Yahoo FinanceKRRO
      Korro Bio reports preclinical data for AATD treatment KRRO-111
      Oct 22Investing.comKRRO
      Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
      Oct 22Yahoo FinanceKRRO
      CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
      Oct 20Yahoo FinanceCAMPKRRO
      Korro Bio at Chardan’s 10th Annual Healthcare Conference: RNA push
      Oct 20Investing.comKRRO
      Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 16Yahoo FinanceKRRO
      Oppenheimer Reaffirms Their Buy Rating on Korro Bio (KRRO)

      Tipranks Press Release.

      Oct 7The Globe and MailKRRO
      H.C. Wainwright reiterates Korro Bio stock rating on trial dosing
      Oct 6Investing.comKRRO
      Korro Bio doses first patients in urea cycle disorder trial
      Oct 6Investing.comKRRO
      Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
      Oct 5Yahoo FinanceKRRO
      Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
      Sep 11Yahoo FinanceKRRO
      Korro to Participate in Upcoming Investor Conferences

      CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for...

      Aug 27BarchartKRRO

      This is the newest page. Registered accounts read further back.